What development phase is Oxiamin in?

Oxiamin is FDA-approved (marketed).

What is the generic name of Oxiamin?

INOSINE is the generic (nonproprietary) name of Oxiamin.

Last reviewed 2026-04-20 · How we verify

Oxiamin (INOSINE)

FDA-approved active Small molecule Quality 6/100

At a glance

Generic name	INOSINE
Drug class	inosine
Modality	Small molecule
Therapeutic area	Cardiovascular
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials
Immune Defense Protein Impact On Respiratory Immune Outcomes (NA)
De-implementing Inhaled Nitric Oxide for Congenital Diaphragmatic Hernia (PHASE4)
Molecular Analysis of Thrombocytopenia and Cancer (MATAC): Investigating Antigenic Mimicry Between Platelets and Tumor Cells in Patients With Immune Thrombocytopenia (ITP) Associated With Cancer
Phase 1 Study of UniCAR02-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies (PHASE1)
Outpatient Induction of Labour Using a Double Balloon Transcervical Catheter in Low-risk Pregnant Women: a Two-centre Open Prospective Randomised Controlled Trial - OutCRIB (NA)
Evaluation of Impression Accuracy: Digital Scanner Versus Analog Technique
Efficacy of Inhaled Nitric Oxide in Congenital Diaphragmatic Hernia (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Oxiamin CI brief — competitive landscape report
Oxiamin updates RSS · CI watch RSS